As Second Vice President, Olivier Laureau will continue to defend the pharmaceutical sector, bringing in Servier’s values as well as defending the interests of the EFPIA European Mid-Size Pharmaceutical Companies.

He will be working together with the President (Hubertus Von Baumbach from Boehringer Ingelheim) and the first Vice-President (Lars Fruergaard Jørgensen from Novo Nordisk) leading the work of the federation for a two-year mandate.

“Recent events have demonstrated the key role medical innovation plays in keeping our society safe and healthy” said Olivier Laureau.  “Our ambition is for Europe to be a world leader in life science. Realising that goal means EFPIA and its membership working with the EU and Member States to build a world-class regulatory system, a strong and predictable IP framework and a next generation life sciences eco-system that delivers for patients across Europe and around the world.”

Servier is a member of EFPIA since 1997.

Read EFPIA’s press release: zveze EFPIA

( new-presidency-team-at-efpia-committed-to-working-with-eu-and-member-states-to-build-back-better-from-covid-crisis/)